
A company briefly owned by Allergan, which recently vowed to limit price hikes on its medicines, is the latest drug maker to be accused of price gouging in the United Kingdom.
From 2008 to mid-2016, Auden Mckenzie raised the price of its generic version of 10 mg hydrocortisone tablets by more than 12,000 percent, compared with cost of a brand-name version that was sold by a different company before the generic came on the market.
Would this argue the UK is getting equal treatment to balance out the reasonable price the UK gets for the product that lead today’s Little?